Kornimate/medical-research-clean huggingface dataset:
contrast sensitivity and diabetic macular edema

Conditions: DIABETES MELLITUS; DIABETIC RETINOPATHY; MACULAR EDEMA

Summary: contrast sensitivity is a tool use to evaluate the visual function in all patients. it can be modified by different pathologies or by age. the purpose of this study is to identify the changes that could be in relationship with the course of diabetic retinopathy comparing with diabetic patient without retinopathy and in patients with diabetic macular edema so if it is a difference, research for therapeutic strategies to improve it in this patients.

contrast sensitivity is defined as a subjective measurement, it is the ability to separate the image between figure and background, taking into account the minimum amount of light required; it is evaluated by the contrast threshold, which is the smallest amount of contrast needed to be able to see a target and solve their characteristics, would be his reciprocal value. medina et al. curve reported in healthy mexicans sc 5 to 80, where \> 51 years have decreased compared to contrast sensitivity studies international; further that contrast sensitivity in older groups of 41 years is decreased high frequency.

Eligibility criteria:
inclusion criteria: * diabetic patients * 40-60 years old * any gender * visual acuity \>0.25 in decimal equivalent, exclusion criteria: * patients with cataracts or other maculopathy * patients with contact lenses * patients with refractive error \>6.00dp * patients with previous ocular surgery
msc administration for the management of type 1 diabetic patients

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of this study is to evaluate whether the administration of multipotent stromal cell also referred as to mesenchymal stem cells (mscs), modified type 1 diabetes progression.

aim: to evaluate whether a single intravenous administration of allogeneic bone marrow-derived multipotent stromal cell also referred as to mesenchymal stem cells (mscs), modified endogenous insulin secretion capacity and exogenous insulin requirement in patients with type 1 diabetes mellitus. participants: 10, females or males, 18 years or older, diagnosed with type 1 diabetes mellitus at most 1 year before enrollment, under exogenous insulin treatment, with pancreatic reserve of insulin. intervention: intravenous administration of a single dose (2-3 millions/kg) of allogeneic mscs. follow up: before and 1, 6, 24 months after msc administration.

Eligibility criteria:
inclusion criteria: * differential diagnosis of type 1 diabetes * diagnosed performed at most 1 year before enrollment * pancreatic reserve of insulin higher than 0.8 nmol/l/h * good general health status * informed consent of patient * consent of treating physician * proved psychiatric competence to be enrolled in a clinical study exclusion criteria: * pregnancy * significant comorbidities * hiv, hbv, hcv, htlv-1, hltv-2 or vdrl positive

Keywords: type1 diabetes mellitus multipotent stromal cell mesenchymal stem cell insulin pancreatic reserve disease progression
evaluation of ait study

Conditions: Personality Disorders; Borderline Personality Disorder

Summary: specialized treatment of personality disorders (pd) in youth has been neglected for a long time, because these disorders were not diagnosed before the age of 18. since 2013 the age threshold has been dropped in the diagnostic and statistical manual (dsm)-5, and such change is also announced for the international classification of diseases (icd)-11. there is broad consensus from both scientific evidence and clinical experience that specialized early interventions in adolescents with pd are urgently needed. in the last decades a number of specialized psychotherapeutic treatment programs have been developed. despite their conceptual differences, many of the treatment models have shown significant effects in the treatment of pd in adults. however, the treatment of adolescents with pd remains difficult and further enhancement and development of treatments is needed. given the different therapeutic approaches available, the present project aims to go beyond the comparison of integral therapeutic models in the classical outcome study design. while outcome research is important to build on the evidence of the effectiveness of an intervention, it contributes little to its understanding and refinement. the aim of the present multi-center project is to compare two therapeutic methods used in routine care: * adolescent identity treatment (ait) * dialectic behavioral treatment for adolescents (dbt-a) treatments will be performed at different study centers and compared using the same measures of outcome. the main outcome will be psychosocial functioning. additionally, the psychotherapy process will be investigated to explore specific and unspecific mechanisms of the therapeutic process, its outcome and mediators.


Eligibility criteria:
inclusion criteria: * identity diffusion (aida t-score \> 60) * borderline criteria (skid-ii) exclusion criteria: * intelligence quotient (iq) \< 80 * psychotic disorder * pervasive developmental disorders * heavy and persistent substance abuse * major somatic or neurological disease * hospital treatment

Keywords: psychotherapy psychotherapy process therapeutic alliance psychotherapeutic change psychophysiology
evaluation of tk3 in improving quality of life in patients with malignancy under chemotherapy

Conditions: Cancer

Summary: the association of nutritional supplement tk3 to conventional treatment of cancer patients reduces the intensity and frequency of toxic effects and side effects caused by adjuvant or palliative treatments for the protection of healthy tissues, resulting in a better quality of life.


Eligibility criteria:
inclusion criteria: * patient consent: informed consent and informed consent signed and dated by the patient (or his legal representative) and the professional who has obtained the consent. must be delivered before inclusion. this term must be read and explained to the patient. * patients female or male, regardless of race or color.able to ingest oral medication. * patients 30-80 years, with malignancy, clinical stage iii or iv on chemo or hormone therapy. * patients who have a karnofsky level between 60 and 80. exclusion criteria: * no agreement to sign the deed of consent. * need for use of parenteral nutrition. * the need for food supplement already approved. * inability to receive the drug orally. * participation in another clinical trial involving chemotherapy drugs. * women being sexually active, which does not agree to adhere to the contraceptive methods adopted. * women lactating * any problem or condition that the investigator in the trial could be harmful to the patient.
investigation of the epidemiological factors associated with the development of amyotrophic lateral sclerosis (als)

Conditions: ALS

Summary: investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (als) in israel with a view to future international collaboration. particularly addressing:- 1. differences between ethnic subgroups 2. differences between immigrant and native-born populations 3. differences according to military service profile clinical features gathered at each routine visit ,throughout the entire course of the disease, will be recorded in database format, in order to correlate with potential epidemiological factors.

investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (als) in israel with a view to future international collaboration. particularly addressing:- 1. differences between ethnic subgroups 2. differences between immigrant and native-born populations 3. differences according to military service profile clinical features gathered at each routine visit ,throughout the entire course of the disease, will be recorded in database format, in order to correlate with potential epidemiological factors. the clinical features will include pattern of onset, details of full clinical exam ( including alsfrs-r score, power, reflexes, and other signs of upper or lower-motor neuron dysfunction. correlations between different clinical parameters themselves will be made, as well as correlation between clinical parameters and other epidemiological factors.

Eligibility criteria:
inclusion criteria: - suspected, possible, probable ,definite als exclusion criteria: -
carotid atherosclerotic plaque study

Conditions: Atherosclerosis

Summary: first, to establish a comparison of the pathophysiology of carotid atherosclerosis and the genetic and environmental variables that cause those plaques to become symptomatic. second, to differentiate between vulnerable plaque and other types of plaque using ultrasound elastography, mri data, trans-cranial doppler along with rf (radio frequency) analysis of back-scattered ultrasonic echoes.

this is a multi-investigator study based on the pathophysiology of carotid atherosclerosis and the variables that cause certain plaques to become symptomatic.patients enrolled in this study will be those patients undergoing a carotid endarterectomy. this will include both symptomatic and asymptomatic patients, and there are a variety of atherosclerotic risk factors representing this patient population.patients may or may not have had strokes or transient ischemic attacks (tias).pre-operatively patients will be reviewed for their medical history and atherosclerotic risk factors. plaque removed during routine carotid endarterectomy will be examined for study purposes.

Eligibility criteria:
inclusion criteria: * male and female patients aged 18-80 presenting for carotid endarterectomy exclusion criteria: * patients not felt suitable for carotid endarterectomy and those with impaired decision-making capacity
effect of s-ketamine in cesarean section combined anesthesia

Conditions: Postoperative Pain

Summary: to compare the anti-hyperalgesia effect between s-ketamine with placebo for maternal receiving elective cesarean section under combined spinal and epidural analgesia. based on this study the investigators intend to verify the role and potential mechanism of s-ketamine combined anesthesia in alleviating hyperalgesia after cesarean section, prove that it can reduce hyperalgesia and postoperative pain. explore the role of s-ketamine in alleviating postoperative hyperalgesia in different pca ways and explore the safety of s-ketamine in the perilactation


Eligibility criteria:
inclusion criteria: * asa status i-iii * age 20 to 45 * 37-42 weeks gestation * undergo elective cesarean section with subarachnoid anesthesia * participate in this study and sign informed consent exclusion criteria: * patients with contraindications for cesarean section * patients with contraindications of combined spinal and epidural anesthesia * patients with severe systemic disease * alcoholism and long-term use of anti-inflammatory and analgesic drugs * patients who were unable to cooperate or refused to participate in the trial * patients with contraindications to esketamine and hydromorphone

Keywords: s-ketamine cesarean section hyperalgesia
cytokines in femtosecond laser-assisted cataract surgery

Conditions: Cataract

Summary: the investigators performed the current study to compare: 1) the pain scores by visual analogue scale; 2) the cytokines concentrations in aqueous humor by human cytokine antibody array; 3) the prostaglandin e2 (pge2) concentrations by enzyme linked immunosorbent assay (elisa); 4) the pupil behaviors by image j between first-eye and second-eye in bilateral cataract patients undergoing sequential femtosecond laser-assisted cataract surgery (flacs). to our knowledge, this is the first intraindividual study investigating contralateral effect in flacs. the findings from the current study may broaden our understanding on the mechanism of sympathetic reaction, help to improve clinical performances, and provide strong clinical guidance for cataract surgeons.


Eligibility criteria:
inclusion criteria: * consecutive cataract patients aged 40-80 years, regardless of gender, with bilateral similar grades of lens opacity, and scheduled for sequential flacs were enrolled in this study. exclusion criteria: * history of ocular or systematic inflammatory diseases like uveitis, rheumatism or other autoimmune diseases; * previous ocular surgery or trauma; * preoperative glaucoma, zonular weakness, lens dislocation, or poor pupil dilation (measured pupil diameter \<5.0 mm) or synechiae; * use of systemic or topical steroids, non-steroidal anti-inflammatory drugs (nsaids), alpha-adrenergic antagonist, or pain relief medications within 1 month prior to surgery; * patients with baseline eye pain, having anxiety, muscle spasm around the eye or involuntary eye movement disorders which may influence the pain score; * eyes needing for any other type of anesthesia, failed to obtain \> 100 μl aqueous humor (ah) or encountered intra-operative complications like posterior capsule rupture

Keywords: cataract; cytokine; pain; miosis
research on diagnosis and prognosis of myocardial ischemia level using magnetocardiography

Conditions: Stable Ischemic Heart Disease; Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia

Summary: magnetocardiography (mcg) is a non-invasive and accurate method of detecting myocardial ischemia. however, the previous mcg is limited in clinical practice due to its high working conditions and limited sensitivity. the next-generation mcg based on optical pumped magnetometer (opm) has the advantages of high sensitivity, high reliability, high usability and low cost, which makes it suitable for most medical scenarios. thus, this prospective single-center study aimed to use opm mcg to explore its diagnostic efficacy and predictive value for myocardial ischemia. participants who will receive coronary angiography examinations will be enrolled in this study. participants enrolled in the study will also have a 1, 3, 6, 12, 24, 36, and 48-month follow-up for analysis of adverse cardiac events.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old; 2. those who are suspected of coronary heart disease and scheduled to undergo coronary angiography; 3. sign the informed consent. exclusion criteria: 1. complex arrhythmia, including frequent premature atrial beats, premature ventricular beats, atrial fibrillation, atrial flutter, and complete bundle branch block; 2. severe hypertension (\> 180/110 mmhg); 3. congenital heart diseases, valvular heart diseases, or implantation of pacemakers or drug pumps. 4. severe thoracic or pulmonary diseases, thoracic malformation, or history of thoracic surgery; 5. pregnant or breastfeeding women; 6. claustrophobia, or those who can't lie still for 2 minutes in a confined space; 7. allergy to contrast agent; 8. renal impairment: serum creatinine \> 2,0 mg/dl (176.8 μmol/l) or those who are receiving hemodialysis; 9. other diseases, including malignant tumors, organ transplantation, and candidates for organ transplantation; 10. history of alcohol or drug abuse (cocaine, heroin, etc.); 11. participating in clinical studies of other drugs or devices without reaching the time limit for the primary endpoint; 12. those who aren't suitable for inclusion due to other reason.
robot-assisted training of the upper limb in persons with multiple sclerosis: an randomized controlled trial

Conditions: Multiple Sclerosis

Summary: with this randomised intervention study, the investigators want to investigate the training effect of an 8 week training regime, using a robot-assisted training system in persons with ms. besides conventional therapy, study participants in the experimental group will train 3 times per week during 30 minutes, using the haptic master. research questions focus on the effects of additional robot assisted training on range of motion, movement quality and clinical tests for the upper limb in persons with ms. evaluation by means of questionnaires and clinical outcome measures occured at baseline, after 4 weeks, after 8 weeks and at 16 weeks of follow-


Eligibility criteria:
inclusion criteria: * diagnosed with multiple sclerosis (mcdonald criteria), upper limb dysfunction due to muscle weakness (motricity index \ 18 years exclusion criteria: * ms relapse or glucocorticosteroid treatment in the last month before the start of the study, upper limb paralysis (motricity index \< 18), other sever limitations, influencing participation (cognitive, visual)
a japanese phase 1 trial of c-met inhibitor msc2156119j in subjects with solid tumors

Conditions: Solid Tumors

Summary: this is a japanese multicenter, open-label, phase 1 study to evaluate safety and efficacy of msc2156119j in subjects with malignant solid tumor which is refractory to standard therapy or to which no effective standard therapy is applicable.


Eligibility criteria:
inclusion criteria: * a subject with a histologically or cytologically confirmed diagnosis of malignant solid tumor which is refractory to standard therapy or to which no effective standard therapy is applicable * an archived tumor tissue is available or biopsy of tumor tissues can be newly performed * a japanese male or female, age greater than or equal to (\>=) 20 years * a subject who has read the subject information sheet and understood the details of this clinical trial, and is willing and able to give his/her informed consent. * a female of child-bearing potential must have a negative blood pregnancy test result at her screening period. a female subject of child-bearing potential must be willing to avoid pregnancy by using an adequate method of contraception life expectancy is at least 3 months * other inclusion criteria apply exclusion criteria: * known human immunodeficiency virus (hiv) positivity, active hepatitis c, or active hepatitis b * presence of liver fibrosis or liver cirrhosis that has been histologically diagnosed * signs or symptoms that suggest transmissible spongiform encephalopathy * received major surgery within 6 weeks before day 1 in cycle 1 * known drug abuse or alcohol abuse * known hypersensitivity to any of the trial treatment ingredients * hematological test abnormalities * renal impairment as defined in the protocol * liver dysfunction as defined in the protocol * history or presence of central nervous system metastasis * history or presence of disease or condition that may hamper compliance or absorption of the investigational medicinal product (imp) due to difficulty in swallowing or absorption * poor performance status of eastern cooperative oncology group performance status (ecog ps) \>= 2 * received any anti-cancer therapy days received extensive prior radiotherapy that irradiates more than 30 percent of bone marrow * received any radiotherapy within 4 weeks before day 1 in cycle 1 * pregnancy and lactation period * history of receiving treatment with any c-met signaling pathway inhibitor * participation in another interventional clinical trial within the past 30 days from day 1 in cycle 1 * other significant disease that in the investigator's opinion would exclude the subject from the trial * legal incapacity or limited legal capacity * other exclusion criteria apply

Keywords: solid tumors msc2156119j c-met inhibitor japanese phase 1
cardiopulmonary resuscitation witnessing by a relative

Conditions: Cardiac Arrest

Summary: the bereavement generated by the loss of a family member can induce pathological situations: depressive state, anxiety, post-traumatic stress disorder and complicated grief. these morbid factors can be influenced by the death circumstances and in particular by the possibility given to the family to attend the medical management of the patient. this clinical trial aims to evaluate the psychological consequences of bereavement on the relatives according to the possibility of witnessing the cardiopulmonary resuscitation of a family member. this possibility lies within the scope of a strategy of global management of the relatives.

this clinical trial aims to compare the presence of post-traumatic stress disorder on a relative related to the death of a family member: test group: the medical team will propose to the relative to witness the cardiopulmonary resuscitation. control group: the medical team will not modify its usual management of care.

Eligibility criteria:
inclusion criteria: * patient victim of a cardiac arrest and resuscitation initiated * occurrence of cardiac arrest at home * presence of a relative : * husband or spouse * father or mother * son or daughter * brother or sister * patient's age ≥ 18 years * relative's age ≥ 18 years * consent of the relative to the participation in the study exclusion criteria: * no understanding of the explanations (language problem, important agitation) * non-affiliated to social security

Keywords: out-of-hospital emergency cardiac arrest post-traumatic stress disorder
the effect of aerobic exercise in alexithymic individuals with chronic pain

Conditions: Chronic Pain; Quality of Life; Alexithymia

Summary: it was aimed to investigate the effect of aerobic exercise on pain, alexithymia level and quality of life in young alexithymic individuals with chronic pain. there is no study in the literature comparing the effectiveness of aerobic exercise on alexithymia and chronic pain. since our study will be the first study to investigate the subject, we foresee that it is scientifically important and will shed light on future studies. in addition, it is planned to make national or international papers and publications after the study is completed.

in the study, after the necessary permissions are obtained, the graded chronic pain scale (ecas) and toronto alexithymia scale-20 (tas-20) will be sent to the students who are studying at kto karatay university and whose age range is between 18-25 years. among the students who fill out the form voluntarily, individuals who mark the 3rd or 4th option in the first question in the dkas and who have a total score of 52 and above in the tas-20 scale will be identified. among these individuals, a total of 40 people will be included in the study randomly with a computer program. these participants will again be randomly divided into two groups as the control group (n=20) and the exercise group (n=20).

Eligibility criteria:
inclusion criteria: * to be between the ages of 18-25 * to mark the 3rd or 4th option in the first question in the dkas * to have a tas-20 total score of 61 and above exclusion criteria: * presence of any physiological or psychological disease that may interfere with the exercise protocol to be applied